About US
Takis is a Biotechnology Company based in Rome, Italy. Our group has more than 10 years of experience in drug discovery; we have contributed to the validation of new targets for the treatment of chronic viral diseases and cancer and to a number of IND/CSA filings in the areas of virology and oncology. Our team is also recognized for the conception and implementation of a number of innovative technologies with the goal to improve in vivo gene transfer, regulation of gene expression and immunogenicity.
Takis main focus is the development of therapeutic cancer vaccines against tumor antigens which play a role in tumor development and maintenance.
Takis plans to bring its core vaccine candidates through Phase I and Phase II proof-of-concept trials.
Takis as a CRO provides a variety of research services in the areas of Oncology, Immunology, Infectious Diseases and novel preclinical models.
Start navigating Takis opportunities!
Our Mission
Contribute to the continuous improvement of human health and patient care through:
- Identification of novel targets for cancer immunotherapy and development of clinical candidates with associated biomarkers;
- Discovery, research and development (R&D) services to pharmaceutical, biotechnology and medical device companies as well as to academic centers
Research Operation
 |
 |
In vitro/In vivo studies: Castel Romano Rome, Italy and c/o Biogem Ariano Irpino (AV), Italy
Key expertise
o Cancer Immunotherapy
o Monoclonal and Polyclonal Antibodies
o Target Identification in Oncology and Infectious Diseases
o Primary human tumors
o In vitro Studies
o Preclinical Models
o Technology Transfer
Scientific Collaborations
Takis has established several collaborations with research institutes and clinical centers in different areas of expertise.
 |
Lung Cancer Stem Cells |
 |
Melanoma Immunotherapy |
 |
Stromal Antigen Vaccine |
  |
Veterinary Cancer Vaccines |